By Ben Butkus

This article was originally posted on Dec. 20.

Canada's Spartan Bioscience said this week that its CYP2C19 molecular test, which runs on the company's Spartan Rx PCR-based point-of-care testing platform, has received a CE Mark for in vitro diagnostic use in Europe.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.